Moreover, the presence of TLSs and the elevated expressions of CCR7 and VEGF-C in tumor tissues can serve as indicators of a favorable response to anti-PD-1 immunotherapy in HCC patients. This evidence concerns the gene CCR7 and hepatocellular carcinoma.